Navigation Links
Inverseon Focuses on Mucous and Smoking Cessation

SAN FRANCISCO, Jan. 12, 2012 /PRNewswire/ -- Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, it is focused on smoking cessation as the initial indication for INV102.

William J. Garner, MD, Chairman, said, "The prioritization of smoking cessation, and also an inhaled COPD program, makes sense for Inverseon given the regulatory hurdles in key markets. We credit Dr. Glass for this refinement of our priorities. Mitchell Glass's extensive drug development background, relationships with the respiratory community, and experience with the strategic development and commercialization of therapeutics will be a major asset for Inverseon as the company advances its lead product (INV102) towards commercialization."

"Inverseon has provided critical support for the use of beta-adrenergic receptor inverse agonists for treating respiratory diseases. The founder's basic scientific breakthroughs provide a rational explanation for our previous success in developing carvedilol for heart failure while I was at SmithKline Beecham and provide a rationale for using INV102 for treating COPD. Two Phase II asthma trials are supportive of further development for chronic pulmonary diseases," said Dr. Glass. "We are now collaborating with granting agencies for further development of INV102 in asthma and preparing for expanded internal Phase II clinical trials demonstrating safety and efficacy of INV102 as a treatment to aid smoking cessation and chronic bronchitis."

About Inverseon, Inc.
Founded in 2004, Inverseon is a privately held company with product development programs in Phase II that target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as COPD and asthma. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at

Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.


William J. Garner, MD  
(917) 653-0470

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Inverseon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
2. Nature article focuses on tinnitus treatment
3. ONR lecture focuses on Brazils growth in global science and technology
4. Florida Water Resources Annual Conference Focuses on Numeric Nutrient and Other Water Issues
5. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
6. Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
11. ECBCs Environmental BioMonitoring Laboratory Focuses on the Future
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):